“After a long and highly productive career in public service, Billy has decided to retire from FDA and explore other opportunities while continuing his focus on improving the lives of patients with neurological diseases,” Peter Stein, MD, director of the agency’s office of new drugs and the center for drug evaluation and research, said in an emailed statement.
The FDA named Teresa Buracchio, MD, to be deputy director and acting office director of the neuroscience sector.
